CSIMarket
 


Durect Corp  (DRRX)
Other Ticker:  
 

Cumulative Durect's Leverage Ratio for Trailing Twelve Months Period

DRRX's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

DRRX Leverage Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth -58.67 % -85.02 % -67.77 % -56.76 % -45.56 %
Y / Y Total Liabilities Growth 17.47 % 24.51 % 27.83 % -5.95 % -7.81 %
Leverage Ratio for Trailing Twelve Months Period 2.53 1.82 1.24 0.9 0.74
Total Ranking # 2933 # 2705 # 2295 # 2101 # 1711
Seq. Equity Growth 161.93 % -64.15 % -38.6 % -28.32 % -5.04 %
Seq. Total Liabilities Growth -11.29 % -1.56 % 30.82 % 2.84 % -5.98 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite debt repayement of -11.29% in III. Quarter, Leverage Ratio for Trailing Twelve Months Period improved to 2.53, above Durect's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 381 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Durect. While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are DRRX's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 382
Sector # 774
S&P 500 # 2878


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.16 1.88 0.3
(Sep 30 2017)   (March 31, 2014)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage Ratio for Trailing Twelve Months Period
Fortress Biotech Inc   6.48 
Mallinckrodt Plc  6.42 
Aslan Pharmaceuticals Limited  6.31 
Puma Biotechnology Inc   6.31 
Nabriva Therapeutics Plc  6.19 
Abbvie inc   6.18 
Zyversa Therapeutics Inc   6.00 
Soligenix inc   5.64 
Kala Bio inc   5.42 
Ionis Pharmaceuticals Inc  5.16 
Collegium Pharmaceutical Inc   5.14 
Harrow Inc   5.09 
Therapeuticsmd Inc   5.03 
Nrx Pharmaceuticals Inc   4.99 
Cingulate Inc   4.98 
Adc Therapeutics Sa  4.96 
Amicus Therapeutics inc   4.95 
Alimera Sciences Inc   4.88 
Cv Sciences Inc   4.87 
Intercept Pharmaceuticals inc   4.85 
Ultragenyx Pharmaceutical Inc   4.79 
Lifecore Biomedical Inc   4.72 
Journey Medical Corporation  4.69 
Clene Inc   4.66 
Ocular Therapeutix Inc   4.50 
Travere Therapeutics Inc   4.50 
Ironwood Pharmaceuticals inc   4.46 
Sarepta Therapeutics Inc   4.29 
Janone Inc   4.05 
Eterna Therapeutics Inc   3.98 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com